Translate AMICOR contents if you like

Monday, July 02, 2018

NLY01 Exenatide, Lixisenatide, liraglutide and dulaglutide in PD

Experimental Drug Stops Parkinson’s Progression: Mouse Study

by Neuroscience News
A newly developed experimental drug, that contains similar compounds to those in diabetes medications, slows the progression of Parkinson's in mouse models of the disease, researchers report.
Similar drugs to NLY01 already approved by the Food and Drug Administration for the treatment of type 2 diabetes include exenatide, lixisenatide, liraglutide and dulaglutide, each of which can cost approximately $2,000 for a 90-day supply. NLY01 is a long-acting drug with improved the brain penetration compared to these approved drugs for diabetes.

No comments: